Boston Scientific plans to acquire Relievant Medsystems, the company behind the Intracept intraosseous nerve ablation system.
The deal values Relievant Medsystems at $850 million, and additional payments are expected over the next three years, according to a Sept. 19 news release.
Intracept is a minimally invasive, implant-free outpatient procedure aimed to address lower back pain. Its efficacy is backed by clinical trials.
The acquisition is explected to close in the first half of 2024.
SynerFuse is partnering with Velentium Medical to scale the SynerFuse e-TLIF implant, according to a March 21 news release. Velentium…
Here are four spinal devices that have earned FDA approval, as reported by Becker’s since Jan. 24:
Comments are closed.